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Abstract
Background: P38 mitogen activated protein kinase is an intermediary signal transduction factor with context-specific
roles in breast cancer. Recent mechanistic studies add to the growing consensus that P38 is a tumour suppressor, and
it may represent a novel target for breast cancer treatment. The aim of this study is to add definitive data on the
prognostic value of P38 and its link with biomarkers in primary breast cancer.
Methods: A large, well-characterised series of 1332 primary breast cancer patients with long-term clinical follow-up
was assessed for P38 expression by immunohistochemistry. Association of clinicopathological factors and a panel of
breast cancer biomarkers was determined by chi-squared test, and multivariate survival analysis was performed using
Cox Proportional Hazards regression modelling.
Results: This study shows that nuclear P38 is co-expressed with nuclear hormone receptors (p < 0.001) and is an
independent prognostic marker of good long-term clinical outcome in primary breast cancer (hazard ratio 0.796, 95%
confidence interval 0.662–0.957, p = 0.015). Significant association was found between expression of P38 and markers
of DNA repair including nuclear BRCA1 and RAD51, and cleaved PARP1 (all p < 0.001).
Conclusions: The findings support the proposed role for P38 as a tumour suppressor in breast cancer via upregulation
of DNA repair proteins and provide novel hypothesis-generating information on the potential role of P38 in adjuvant
therapy decision making.
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Background
Adjuvant treatment of breast cancer is determined pri-
marily by tumour biology. P38 mitogen activated protein
kinase (MAPK) has been proposed as a potential target
for the adjuvant treatment of breast cancer, but its prog-
nostic value in this context has yet to be defined.
P38 MAPKs are essential components of intracellu-
lar signal transduction. Cancer cells respond to extra-
cellular stimuli such as pro-inflammatory cytokines
and oxidative stress via MAPK pathways mediated by
ERK, JNK, and p38 protein kinase activation [1, 2].
Once phosphorylated, P38 in cytoplasm translocates
to the nucleus where the signal is cascaded by phos-
phorylation of protein kinases and transcription fac-
tors (TFs) [3]. Integration of the cellular signal by
downstream TFs such as cyclic-AMP dependent TF2
(ATF2) and TP53 determines gene expression pro-
grammes that ultimately dictate phenotypic response
[4–6].
In 70% of breast cancer, the driving TF is oestrogen
receptor (ER) [7]. Along with progesterone receptor (PR),
expression of ER defines luminal breast cancer and is asso-
ciated with good prognosis and response to endocrine
therapy [8]. The role of P38 as an intermediary signal* Correspondence: mrzear1@nottingham.ac.uk
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transduction factor in this context is complex, and
evidence of its prognostic value is mixed [9–12].
Emerging mechanistic data add to a growing consensus
that P38 is a tumour suppressor in breast cancer [5, 13–
15]. These data may have important clinical implications,
for example in defining the clinical context in which small
molecule inhibitors of P38 may have a role in breast can-
cer treatment. However, to date, clinical cohorts investi-
gating the role and prognostic value of P38 in breast
cancer have been limited in size (N= 45 to 335) and con-
clusions are inconsistent between the studies [16–18]. To
determine the context-specific roles of P38 in breast can-
cer, e.g. by molecular subtype (luminal, HER2 positive or
triple negative), large clinical cohort studies are required.
The aim of this study is to address the need for
definitive data on the co-expression of P38 with key
clinicopathological markers including ER and HER2
and its association with clinical outcome. Data from
this large (N = 1332), clinically and molecularly anno-
tated dataset with long-term clinical follow-up (median
166 months, range 1–308 months) is interpreted along-
side current mechanistic data on P38 in breast cancer
and the Molecular Taxonomy of Breast Cancer Inter-
national Consortium (METABRIC, N = 1980) external
dataset (accession number EGAS00000000098).
The study shows that co-expression of nuclear phos-
phorylated P38 (p-P38) and nuclear hormone receptors
ER and / or PR is associated with good long-term clin-
ical outcome in primary breast cancer. In support of the
emerging consensus that P38 is a tumour suppressor,
the current study also demonstrates that nuclear p-P38
is an independent marker of good prognosis in all breast
cancer subtypes. In support of a recent finding that P38
positively regulates DNA repair [15], the current study
shows that nuclear p-P38 is associated with nuclear
expression of DNA repair markers BRCA1 and RAD51,
and cleaved PARP1. These findings have important
implications for breast cancer prognostics and for the
clinical application of P38 inhibitors.
Methods
This was a retrospective study of 1339 primary invasive
BC patient samples within a previously constructed tissue
microarray (TMA), as previously described [19, 20]. All
patients were treated in Nottingham University Hospital
NHS Trust between 1989 and 1998. The average age of
patients was 54 years (range 18–71). Clinical and patho-
logical information were available for patients including
patients’ age, tumour histological grade, tumour size,
stage, vascular invasion (VI) and Nottingham Prognostic
Index (NPI) (Table 1). All patients were treated with adju-
vant therapy according to their NPI score and ER status.
NPI score is determined by size, grade and stage of
tumour and is used to stratify patients into risk categories.
If NPI was ≤3.4, prognosis is considered good to excellent
(85% 5-year survival), and no adjuvant treatment was
given. Cases with NPI > 3.4 have moderate prognosis (70%
5-year survival), and systemic adjuvant therapy was given;
endocrine therapy in ER positive (tamoxifen or aromatase
inhibitor, with the addition of goserelin if the patient was
premenopausal), while in ER-negative, systemic chemo-
therapy was given in the form of cyclophosphamide,
methotrexate and 5-fluorouracil (CMF). Outcome data
were collected on a prospective basis.
Overall survival (OS) was defined as the time in
months from the date of surgery to death from any
cause, at a median follow up of 166 months. Table 1
summarises the main clinicopathological criteria of the
patient cohort.
Immunohistochemistry
From TMA blocks, 4 μm sections were cut onto Xtra
slides, which were heated to 60 °C for 10 min and deparaf-
finised using xylene and rehydrated using grades alcohol
series and tap water. Microwave antigen retrieval (Sharp
R-254 M 800 W) was used for 20 min to heat slides with
0.01 M citrate buffer (pH = 6). Immunohistochemistry
(IHC) was conducted using Novocastra Novolink Polymer
Detection System (Code: RE7280-K, Leica Microsystems,
Newcastle, UK) following the manufacturer instructions.
Primary antibodies were used at the following conditions.
Table 1 Patient characteristics (N = 1332)
Variable number %
Age (years) < 50 454 34.2%
≥50 874 65.8%
Tumour size (mm) < 20 646 48.7%
≥20 681 51.3%
Nodal stage 1 810 60.8%
2 406 30.5%
3 111 8.3%
Grade 1 202 15.2%
2 459 34.5%
3 666 50.2%
ER status negative 314 23.8%
positive 1005 76.2%
HER2 status negative 1102 86.7%
positive 169 13.3%
Vascular invasion negative 733 55.0%
suspected (probable) 153 11.5%
positive (definite) 435 32.7%
Distant metastasis negative 826 62.5%
positive 496 37.5%
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Rabbit anti human P38 antibody (Cell Signalling, 1:50)
and rabbit antihuman phosphorylated-P38 (p-P38, Cell
Signalling, 1:200) were incubated for 1 h at room
temperature or overnight at 4 °C, respectively. Slides were
dehydrated in alcohol and cleared in xylene using Leica
Autostainer, then mounted using DPX (BDH, Poole, UK).
Antibody specificity was confirmed by Western blot
using MCF7 cell line lysate. In brief, MCF7 breast cancer
cell line was lysed in RIPA buffer (Sigma Aldrich, UK)
supplemented with 1X protease inhibitor (Sigma Aldrich,
UK) and 1X phosphatase inhibitor (Sigma Aldrich, UK).
Protein lysates were mixed with 4x NuPage LDS sample
buffer (Invitrogen) and 10 X NuPage reducing solution.
Samples were then loaded on (4–12%) SDS-PAGE precast
gel (Novex, Life technologies), blotted on Hybond ECL
nitrocellulose membrane (GE, Healthcare), then blocked
with 5% non-fat dried milk before incubation with P38
antibody (1:1000) or p-P38 antibody (1:1000) for 1 h at
room temperature. HRP anti-rabbit antibody (1:200,
DAKO) was used before developing the membrane using
ECL detection reagent (Amersham, UK) and exposing the
membrane to X-ray film (Kodak, Sigma Aldrich, UK) for
final detection of the protein bands. Single bands resulted
with both antibodies at the expected molecular weights
(Additional file 1: Figure S1).
IHC scoring and statistical analysis
All TMA slides were scanned at 200X magnification and
scored visually using NanoZoomer software (Hamamatsu
Photonics, Welwyn Garden City, UK). Both the staining
intensity (negative, low, moderate and high) and percent-
age of staining were assessed, and a final H-score was cal-
culated per sample. The H score were dichotomised into
two main categories (high and low) using a cut-point value
obtained using X-tile bioinformatics software [21].
Chi-squared (Χ2) test was used to study the association be-
tween the categorised data of P38/p-P38 and clinicopatho-
logical criteria. Kaplan–Meier was used to plot survival
curves of OS and Log-Rank tests were used to estimate their
significance. Cox multivariate analysis was performed using
the log-rank test. A two-tailed p value < 0.05 was considered
significant. Statistical analyses were performed using SPSS 21
statistical software (SPSS IBM Corp, Chicago, USA) and re-
ported in line with REMARK guidelines [22].
Results
Expression of pan-P38 and phosphorylated (p)-P38
Tissue expression of pan-P38 and phosphorylated P38
(p-P38) was assessed in an invasive breast cancer TMA.
Pan-P38 was expressed in the cytoplasm of invasive breast
cancer cells with different staining intensities observed
(Additional file 1: Figure S2, A-C). Phosphorylated P38
expression was mainly nuclear with weak cytoplasmic
p-P38 staining across the different cores observed
(Additional file 1: Figure S2, D-F).
A cut-off value of 110 was used with pan-P38 with
60.3% (N= 703) showing negative/low expression com-
pared to 39.7% of cases with positive/high expression. The
cut-points of cytoplasmic and nuclear p-P38 H-scores
were 80 and 110, respectively. Cytoplasmic and nuclear
p-P38 expression was negative/low in 68.5% (N= 914) and
70.5% (N= 941) respectively, and positive/high in 31.5%
(N= 419) and 29.5% (N= 394), respectively.
Association of P38 with clinicopathological variables and
disease biomarkers
Pan-P38 and nuclear p-P38 expression were significantly
associated with positive expression of nuclear hormone
receptors ER and PR, which define luminal disease (see
Table 2). Neither pan-P38 nor nuclear p-P38 expression
was associated with HER2 expression. There was posi-
tive correlation of both pan-P38 and nuclear p-P38 with
phosphorylated ATF2, a transcription factor downstream
of ERK, JNK and P38 kinases (both p < 0.001, data not
shown). For clarity, further analysis in this study is re-
stricted to factors related exclusively to P38, independ-
ently of ERK and JNK. Cytoplasmic staining of p-P38,
which was globally weaker in intensity, did not validate
the associations seen with pan-P38 or nuclear p-P38,
with the exception of stage (data not shown). Cytoplas-
mic p-P38 was associated with negative expression of
ER. Nuclear p-P38 was associated with a greater number
of favourable prognostic variables, with greater statistical
confidence (i.e. lower p values). Therefore, nuclear p-P38
was taken forward as a more sensitive candidate marker of
clinicopathological features and clinical outcome. Pan-P38
is eliminated from further analysis and discussion. Nuclear
p-P38 is hereafter referred to as ‘p-P38’.
Association of p-P38 with DNA repair markers
There was significant positive association of p-P38 with
nuclear BRCA1 and RAD51 (see Table 3 and Fig. 1). There
was also enrichment of positive cleaved PARP1 expression
in cases expressing high p-P38, although the majority of
cases were positive for cleaved PARP1 irrespective of
p-P38 status (Table 3). No such association was found
between p-P38 and the transcription factor TP53.
Overall survival analysis based on clinicopathological
characteristics, hormone receptor status and P38
expression
Kaplan-Meyer plots of OS by p-P38 status show that the
prognostic significance of P38 is identical in the luminal sub-
type (ER and/or PR positive, including HER2 positive cases)
to the whole cohort (p = 0.001). No significant association
with survival was found in the smaller HER2 positive (ER
and PR negative) or triple negative subtypes (see Fig. 2).
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Nuclear p-P38, which is associated with expression of hor-
mone receptor biomarkers of endocrine therapy response,
ER and PR (Table 2), is an independent prognostic
marker of good clinical outcome in multivariate ana-
lysis (Table 4). Multivariate analysis was performed on
NPI to avoid overlap between the clinicopathological
variables, e.g. size and stage. In ER+/PR+ (luminal)
disease, median overall survival was 250 months in
tumours expressing high nuclear p-P38 versus
197 months for p-P38 negative cases (p = 0.001) (see
Fig. 2b).
From the whole cohort of 1332 patients, 288 were
also included in the METABRIC dataset [23]. Analysis
was performed on the association between both
pan-P38 and p-P38 protein expression and mRNA ex-
pression of MAPK14, the gene encoding the main
P38 isoform in breast cancer, P38α. There was no sig-
nificant association between protein and mRNA ex-
pression, using median MAPK14 mRNA expression as
a cut-off, by Χ2 test (p = 0.77), and no significant link
with overall survival (HR 0.80, 95% CI 0.55–1.17; p =
0.25). Furthermore, there was no significant link be-
tween MAPK14 expression and overall survival in the
complete METABRIC dataset (HR 1.10, 95% CI 0.96–
1.26; p = 0.16).
In patients who received endocrine therapy (ET), i.e.
those with ER+/PR+ disease and NPI ≥ 3.4, overall
survival was compared by nuclear p-P38 expression.
Overall survival for patients who had ET was
233 months for patients with high nuclear p-P38
Table 3 Nuclear p-P38 is associated with DNA repair markers
Variable nuclear p-P38
negative / low high p
nuclear BRCA1 negative 402 (85.4%) 69 (14.6%) < 0.001*
positive 365 (63.6%) 209 (36.4%)
nuclear BRCA2 negative 540 (72.0%) 210 (28.0%) 0.393
positive 44 (66.7%) 22 (33.3%)
PARP1 negative 346 (75.4%) 113 (24.6%) 0.074
positive 373 (70.1%) 159 (29.9%)
cleaved PARP1 negative 114 (85.7%) 19 (14.3%) < 0.001*
positive 563 (71.5%) 224 (28.5%)
nuclear RAD51 negative 327 (82.4%) 70 (17.6%) < 0.001*
positive 184 (62.8%) 109 (37.2%)
TP53 negative 636 (70.6%) 265 (29.4%) 0.337
positive 268 (73.4%) 97 (26.6%)
*p value in bold type indicates statistical significance (p < 0.05, by Χ2 test)
Table 2 Activated P38 is associated with luminal phenotype (ER &/or PR expression) and favourable clinicopathological prognostic
indicators (N = 1332)
Variable pan-P38 nuclear p-P38
Negative/low Positive/high p Negative/low Positive/high p
Age < 50 yrs 187 57.9% 136 42.1% 0.258 318 70.0% 136 30.0% 0.751
≥50 yrs 363 61.7% 225 38.3% 620 70.9% 254 29.1%
Size < 20 mm 232 56.2% 181 43.8% 0.025* 421 65.2% 225 34.8% < 0.001*
≥20 mm 316 63.7% 180 36.3% 516 75.8% 165 24.2%
Stage 1 334 60.5% 218 39.5% 0.890 550 67.9% 260 32.1% 0.007*
2–3 214 59.9% 143 40.1% 387 74.9% 130 25.1%
Grade 1–2 237 55.4% 191 44.6% 0.004* 413 62.5% 248 37.5% < 0.001*
3 311 64.7% 170 35.3% 524 78.7% 142 21.3%
NPI good / medium 440 58.9% 307 41.1% 0.095 760 68.8% 344 31.2% 0.002*
Poor 109 66.1% 56 33.9% 179 79.2% 47 20.8%
VI negative or suspected 354 59.9% 237 40.1% 0.722 602 67.9% 284 32.1% 0.002*
positive (definite) 192 61.1% 122 38.9% 331 76.1% 104 23.9%
ER Negative 167 74.6% 57 25.4% < 0.001* 244 77.7% 70 22.3% < 0.001*
Positive 379 55.3% 306 44.7% 690 68.7% 315 31.3%
PR Negative 265 72.4% 101 27.6% < 0.001* 398 76.5% 122 23.5% < 0.001*
Positive 264 51.4% 250 48.6% 507 67.3% 246 32.7%
HER2 Negative 463 60.5% 302 39.5% 1.000 775 70.3% 327 29.7% 0.237
Positive 66 61.1% 42 38.9% 127 75.1% 42 24.9%
NPI Nottingham Prognostic Index, VI vascular invasion
*p value in bold type indicates statistical significance defined as p < 0.05 by Χ2 test
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expressing tumours, versus 176 months in p-P38
negative cases (p = 0.043) (Fig. 3).
Discussion
There is an emerging consensus, based mainly on mechan-
istic studies, that P38 is a tumour suppressor in breast can-
cer. Such reports have the potential to direct future clinical
studies, but only if the true prognostic value of the factor of
interest is known. Large clinical datasets are required to
define the prognostic role of P38 in breast cancer and its
subtypes with statistical confidence, and thereby provide
essential supportive data for the conclusions of mechanistic
studies and their clinical implications.
Results from the current study provide definitive
evidence from a large clinical series (N= 1332) that nuclear
activated (phosphorylated) P38 (p-P38) is co-expressed with
nuclear hormone receptors (ER and PR), and that the
co-expression of p-P38 with ER and/or PR is prognostic
of good long-term clinical outcome. Nuclear p-P38 is
an independent prognostic marker of good long-term
clinical outcome and is associated with nuclear ex-
pression of DNA repair markers BRCA1 and RAD51.
Interpreted alongside existing mechanistic studies,
these data have important clinical implications.
P38 as a tumour suppressor
Despite some studies supporting context-specific roles
for P38, for example in tamoxifen and HER2-targeted
therapy resistance, there is mounting evidence that in
primary breast cancer P38 has a tumour suppressive
effect [5, 13–15].
Previous studies into the prognostic value of P38 in
breast cancer have been conducted on series of limited
size, or in a specific subgroup or clinical context. For
example, expression of phosphorylated P38 (p-P38) was
assessed by IHC in 96 lymph node positive breast cancer
patients [9]. High p-P38 expression was not significantly
associated with overall survival in the overall cohort.
Subgroup analysis of patients with highly proliferative
tumours (measured by Ki67 expression) indicated that
P38 was a poor prognostic marker; however, this was
not confirmed using multivariate analysis.
The current study provides definitive evidence that
p-P38 is an independent prognostic marker of good
long-term clinical outcome in primary breast cancer. This
supports the consensus that P38 is a tumour suppressor
in breast cancer and thereby substantiates the clinical
implications of key mechanistic studies on P38. This
supports their translation into further clinical study.
For example, a recent report by Canovas et al. [15]
highlights that breast tumour progression relies on P38
signalling in epithelial cells. The purported mechanism
is that P38 protects breast cancer cells by positively
regulating DNA repair. This prevents cell death second-
ary to the accumulation of DNA damage and chromo-
somal instability, and thereby inhibits any selective
advantage of tumour cells that acquire mutations [24].
This supports the function of P38 as a tumour sup-
pressor, and the mechanism is substantiated by the
link between p-P38 and DNA repair markers includ-
ing nuclear BRCA1 and RAD51 in the current study.
This raises the possibility of P38-mediated upregula-
tion of DNA repair in response to cellular stress via
activation of the known BRCA1/RAD51 mechanism
[25]. However, it also provides the rationale for com-
bining taxane-based adjuvant chemotherapy with
small molecule inhibition of P38: to increase DNA
damage and chromosome instability by destabilising
DNA repair mechanisms, and thereby increase the
anti-tumoral response to chemotherapy.
There is also emerging evidence that P38 has a role in
regulation of stromal expansion, thereby inhibiting
breast cancer metastasis [14]. Evidence that P38 is
tumour suppressive in primary breast cancer suggests
that P38 inhibitors do not have a role as sole adjuvant
therapy in primary breast cancer.
Co-expression of P38 and nuclear hormone receptors ER
and PR
The molecular function of P38 in solid tumours is thought
to be cell-type specific [6]. Therefore, the role of P38 may
vary according to the tissue of origin of a particular cancer,
Fig. 1 Nuclear BRCA1 (nBRCA1) and RAD51 (nRAD51) positivity is
enriched in tumours expressing high levels of nuclear phosphorylated
P38 (p-P38+) (p < 0.001 by Χ2 test)
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Table 4 Overall survival analysis based on clinicopathological characteristics, biomarker status and P38 expression
Characteristic Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
p-P38 low reference reference
high 0.735 0.617–0.875 0.001* 0.796 0.662–0.957 0.015*
NPI good/medium reference reference
poor 2.465 2.054–2.959 < 0.001* 2.120 1.731–2.596 < 0.001*
VI negative or suspected reference reference
positive (definite) 1.436 1.225–1.683 < 0.001* 1.161 0.973–1.384 0.097
ER negative reference n/a
positive 0.917 0.764–1.100 0.350
PR negative reference reference
positive 0.711 0.607–0.832 < 0.001* 0.830 0.703–0.980 0.028*
HER2 negative reference reference
positive 1.722 1.393–2.128 < 0.001* 1.486 1.191–1.856 < 0.001*
HR hazard ratio for death (all causes), CI confidence interval, ER/PR oestrogen/progesterone receptor status (by immunohistochemistry)
*p value in bold type indicates statistically significant results (p < 0.05). NPI = Nottingham Prognostic Index; VI = vascular invasion; p-P38 = nuclear phosphorylated P38
a b
c d
Fig. 2 Overall survival by p-P38 status; Nuclear p-P38 is prognostic of overall survival in (a) the whole cohort and in (b) the luminal subtype, with identical
statistical significance by log-rank test. There was no difference in overall survival in (c) the HER2+ or (d) the triple negative subgroup by p-P38 status
Johnston et al. BMC Cancer         (2018) 18:1027 Page 6 of 9
or clinicopathological features such as breast cancer sub-
type (e.g. luminal, HER2 positive, basal). However, existing
evidence of co-expression of P38 with key biomarkers
such as ER and HER2 is derived from small clinical
cohorts, with inconsistency between the cohorts. As
examples, one study (N= 45) found a significant positive
association between protein expression of P38 and ER
[16]. However, in another study (N= 355), expression of
p38 was associated with HER2 and PR, but not ER expres-
sion [18]. Another cohort (N= 140) found that P38 was
significantly associated with ER expression, but only if
HER2 was co-expressed [17].
In the current study P38 activation, i.e. nuclear p-P38,
was associated with ER and PR expression, with high
statistical significance. However, no association was
found between p-P38 and HER2 expression. Analysis by
breast cancer subtype revealed that high P38 expression
was significantly linked to a survival advantage in lu-
minal disease but not in HER2 positive (ER and PR
negative) or triple negative disease. To the best of our
knowledge, our study has the largest sample size investi-
gating the link between P38 and clinical biomarkers such
as ER, PR and HER2.
The link between nuclear p-P38 and nuclear hor-
mone receptors may have important clinical implica-
tions when interpreted alongside mechanistic data.
The findings offer support to previous mechanistic
studies which implicate P38 in the regulation of ER
and PR. Turnover of ER is required for its activity,
enabling it to respond to temporal fluctuations in
oestrogen (oestradiol, E2) and/or the presence of tamoxi-
fen. It has been shown that P38 phosphorylates ER at a
specific site that demarcates the nuclear receptor for turn-
over via the ubiquitin system [26]. In contrast, P38 may
have a role in maintaining the stability of PR [27]. To-
gether with data showing that PR reprogrammes genomic
ER binding to sites associated with favourable clinical out-
come [28], this implies that P38 may confer a good clinical
outcome and response to endocrine therapy by regulating
nuclear receptors.
The current study also demonstrates that for patients
with primary breast cancer treated with endocrine ther-
apy for up to 5 years, high expression of p-P38 remains
prognostic of good long-term survival. However, there
was no significant difference in survival for the first 5–
10 years for patients treated with endocrine therapy
stratified by p-P38 status (high/low). During this period,
endocrine therapy is likely to be the main determinant
of clinical outcome in ER and/or PR positive disease.
In recent years, evidence from pivotal trials such as
MA17R, ATTOM and ATLAS has shown that extended
adjuvant endocrine therapy maintains its benefit for a
longer period [29–31]. However, this is at the cost of
loss of quality of life through side effects such as hot
flushes, cumulative toxicity such as bone demineralisa-
tion, and extended risk of life threatening side effects
such as thromboembolism.
In practice, whether to extend endocrine treatment is
considered on a case-by-case basis. Guidance to predict
the risk of relapse would be welcome in clinical practice
and may include assessment of p-P38 using IHC on the
primary tumour as a marker of long-term outcome. This
hypothesis would need to be prospectively validated in a
randomised clinical trial.
Despite the co-expression of p-P38 with ER and PR,
the current dataset also demonstrates that the prog-
nostic significance of P38 is maintained independently
of biomarkers in current clinical use. This supports
the concept of P38 as a tumour suppressor in breast
cancer.
Future directions
The current study validates existing mechanistic data and
permits generation of new hypotheses, which can be
explored with greater confidence in pre-clinical and
clinical trials of primary breast cancer treatment. For
example, clinical trials of P38 inhibitors in combination
with adjuvant chemotherapy are supported by these data.
The predictive value of p-P38 expression by IHC on
the relative risk of relapse following 5 years of adjuvant
endocrine therapy will require further investigation with
prospective clinical studies. This demonstrates the value
of high quality prognostic data on the generation of new
hypotheses with potential clinical utility.
Fig. 3 Overall survival after endocrine therapy by p-P38 status;
Activation of P38 predicts better long-term outcome in patients
treated with up to 5 years of adjuvant endocrine therapy
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Conclusions
This study provides definitive evidence for the
prognostic value of P38 in primary breast cancer and
its molecular subtypes. The findings support a role for
P38 as a tumour suppressor in breast cancer via upregula-
tion of DNA repair, and provide hypothesis-generating in-
formation on the potential role of P38 in adjuvant therapy
decision making.
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